Background: Although the incidence of neonatal sepsis is decreasing, neonatal sepsis remains a severe life-threatening disease. No current biochemical marker can provide perfect diagnostic accuracy for neonatal sepsis. The aim of this study was therefore to evaluate the accuracy of presepsin (P-SEP) as a novel biomarker of bacterial infection for neonatal sepsis diagnosis.
Neonatal sepsis is the most common cause of morbidity and mortality during the neonatal period. Neonatal sepsis is classified as either early-onset sepsis (EOS; ≤7 days after birth) or late-onset sepsis (LOS; >7 days after birth). 1 Advances in obstetric and neonatal care have decreased the incidence of neonatal sepsis, especially EOS. Currently, the incidence of group B Streptococcus-specific EOS has declined to 0.3-0.4 cases/1,000 live births, and overall the EOS incidence has declined to 0.8-1.0 cases/1,000 live births. Nevertheless, EOS remains a severe life-threatening disease with a mortality rate ranging from 1.5% in term infants to almost 40% in very lowbirthweight infants. 2, 3 Early diagnosis and treatment of neonatal sepsis are important to prevent severe complications. In this era of multi-resistant microorganisms, however, it is also important to avoid the unnecessary use of antibiotics in sepsisnegative infants. On the basis of the Centers for Disease Control and Prevention 2010 guidelines, Escobar et al. reported that, in a cohort of 7,004 infants, 13% of both well-appearing and ill-appearing infants were evaluated for EOS, and 11% were treated empirically with antibiotics, although only 0.04% of the cohort had blood culture-confirmed infection. 4 Concern has arisen regarding the EOS results and the empirical antibiotic treatment of hundreds of thousands of uninfected newborns annually, resulting in maternal-infant separation and significant expenditure. In treating this low-incidence but highly consequential disease, clinicians seek the early identification of infants with EOS, with the goal of identifying those at risk and facilitating antibiotic treatment to prevent progression to severe disease.
Blood culture is the gold standard for the diagnosis of sepsis in newborns, but the long waiting time for results and the high level of false-negatives that are secondary to the small volume of blood used, make it difficult to use blood culture in the antibiotic treatment decision-making process at the beginning of the screening process. 5, 6 Hence, antibiotics are often started empirically in infants with perinatal risk factors or clinical signs suggestive of a bacterial infection. Therefore, various biochemical markers are used to aid decision making regarding antibiotic therapy in neonatal sepsis. 7, 8 Nevertheless, no current biochemical marker can provide perfect diagnostic accuracy.
Presepsin (P-SEP), or soluble CD14 subtype, is a truncated variant of soluble CD14, and pathogens stimulate P-SEP shedding from the surface of various immune cell types, such as macrophages, monocytes, and neutrophils. 9 Although its function is still unclear, P-SEP is believed to interact with B and T cells to modulate specific immune responses. 10 P-SEP has recently been demonstrated to be a reliable diagnostic and prognostic marker of sepsis in adults. 11 Preliminary reference values of P-SEP have mainly been evaluated in infants with LOS. 12, 13 To the best of our knowledge, few studies have been performed on the possible role of P-SEP as a marker for EOS. Therefore, we hypothesized that P-SEP might be an accurate biomarker of neonatal sepsis, and might better discriminate between infection and non-infectious inflammatory conditions than the currently used biomarkers. To test this hypothesis, we performed a prospective study to evaluate changes in P-SEP serum concentration in newborns with and without possible neonatal sepsis.
Methods

Study design and subjects
This was a prospective study conducted at the neonatal intensive care units (NICU) of two hospitals: Shinshu University Hospital and Nagano Children's Hospital, Japan. This study ran from September 2014 to December 2015 and was approved by the local ethics committees of these hospitals. Written informed consent was obtained from the parents of each patient in this study. During this study period, 784 patients were admitted to the NICU. We assigned patients to three groups: the sepsis group; the control group; and the nonsepsis term group. The sepsis group was defined as having positive blood culture associated with clinical signs of sepsis during the neonatal period (<30 days after birth). We chose 18 preterm patients to constitute the control group in an arbitrary order and matched the gestational weeks with those of the sepsis group. In the control group, no antibiotics were used and there was no clinical sign of sepsis. We compared the sepsis group with the control group. We analyzed peak P-SEP over the first 3 days after onset or after birth because in some patients we could not evaluate P-SEP on day 0. The non-sepsis term group consisted of term neonates with initial suspected bacterial infection but whose clinical course and laboratory findings, including negative blood culture, ruled out the possibility of bacterial infection. Neonates with suspected infection presented with one or more of the following risk factors: maternal factors (e.g. prolonged rupture of membranes [PROM] chorioamnionitis, elevated C-reactive protein [CRP] , and intrapartum maternal fever) and neonatal factors (e.g. presence of meconium-stained amniotic fluid, apnea, respiratory problems that required supplemental oxygen, nasal continuous positive airway pressure, and intermittent mandatory ventilation). This definition was based on a previous study that reported elevated CRP between 11 and 70 mg/L in 16/49 uninfected neonates admitted to the NICU with diagnoses of meconium aspiration pneumonia, anoxic encephalopathy, PROM, respiratory distress syndrome, chorioamnionitis, aspiration pneumonia, and transitory tachypnea. 14 In the nonsepsis term group, we measured white blood cells (WBC), CRP, and P-SEP for 3 days after birth. In all cases, we collected blood culture before starting antibiotics.
Blood sampling and biomarker measurements
For blood culture, a blood sample ≥1 mL was obtained from a peripheral vein. Standard laboratory methods were used to identify the microorganisms that grew in the blood sample cultures. A BD BACTEC (Becton, Dickinson and Company, Tokyo, Japan) was used for the blood cultures. WBC and CRP were measured in serum samples at the central laboratory. WBC was measured using Sysmex XN-9000 (JEOL, Tokyo, Japan). CRP was measured using JCA-BM6070 (JEOL, Tokyo, Japan).
Presepsin
For P-SEP measurements, 100 lL blood sample was collected from each patient by heel stick or venous puncture into a tube containing ethylene diamine tetra-acetic acid (EDTA). P-SEP was measured with a rapid chemiluminescent enzyme immunoassay using a PATHFAST immunoanalyzer (Mitsubishi Chemical Medience, Tokyo, Japan). Each test required 100 lL whole blood and was completed in 17 min.
Statistical analysis
We used SPSS version 23 (IBM, Tokyo, Japan) for statistical analysis. The variables were assessed using visual (i.e. histogram and probability plots) and analytical methods to determine whether they were normally distributed. Parametric results are expressed as mean AE SD. Medians of the non-parametric tests are reported with the IQR. Statistical analysis was performed with Student's t-test for parametric continuous variables, and Mann-Whitney U-test for non-normally distributed variables. To evaluate the diagnostic potential of P-SEP, receiver operating characteristic (ROC) curve analysis was performed, including measurements of specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV), and the area under the curve (AUC). P < 0.05 was considered to indicate significant difference.
Results
During this study period, there were 13 newborns in the sepsis group, 18 patients in the control group, and 35 newborns in the non-sepsis term group. Table 1 lists the shows the characteristics of the sepsis group and control group. Table 2 lists the pathogen of sepsis and the date of onset in the sepsis group. Figure 1 shows the changes in P-SEP according to sepsis status for 3 days after onset or birth. P-SEP in the sepsis group was significantly higher than in the control group during this period. The AUC for P-SEP was 0.868 (95%CI: 0.71-1.00; Fig. 2 ). P-SEP 795 pg/mL was established as the cut-off, with 85% sensitivity and 89% specificity. The PPV and NPV were 85% and 89%, respectively. Table 3 lists the change in markers in the non-sepsis group. P-SEP did not change significantly during the 3 days after birth, but WBC and CRP did.
Discussion
In the present study, we have shown that P-SEP may be used in the diagnosis of neonatal sepsis. P-SEP was significantly higher in the sepsis group compared with the control group. Furthermore, P-SEP had better stability than WBC and CRP in the 3 days after birth in the non-sepsis term group.
Several reports have demonstrated the efficacy of P-SEP for the diagnosis of LOS. In 2015, Topcuoglu et al. reported that P-SEP was significantly elevated in preterm infants with LOS and that the best cut-off for P-SEP was 800.5 pg/mL, with sensitivity 67% and specificity 100%. 13 In 2015, Poggi et al. reported that P-SEP decreased even on the first day of treatment, whereas CRP and procalcitonin (PCT) did not differ from baseline. 12 In 2017, Montaldo et al. evaluated 32 preterm newborns with EOS and compared them with nonsepsis preterm newborns: the AUC for P-SEP was 0.97 and the best cut-off was 788 ng/mL, with sensitivity 93% and specificity 100%. 15 In the present study, P-SEP 795 pg/mL was established as the cut-off, with sensitivity 85% and specificity 89%.
Recently, several reports have provided the normal value of P-SEP in neonates. In 2012, Mussap et al. evaluated 26 consecutive non-septic preterm newborns with various severe diseases and reported a mean P-SEP blood level of 643.1 AE 303.8 ng/mL (median, 578 ng/mL). They found no correlation between gestational age and P-SEP blood level in neonates born between 26 and 36 weeks. 16 In 2015, Pugni et al. evaluated 684 healthy neonates (484 at term and 200 preterm). In the term infants, median P-SEP was 603.5 pg/ mL (IQR, 466.5-791 pg/mL; 5th and 95th percentiles: 315 and 1,178 pg/mL, respectively), and in preterm infants, median P-SEP was slightly higher at 620 pg/mL (IQR, 503-864 pg/mL; 5th and 95th percentiles: 352 and 1,370 pg/mL respectively). 17 In the present study, median P-SEP was 501 pg/mL (IQR, 391-604 pg/mL) on day 0 in the non-sepsis term group.
A large number of studies have been performed to evaluate the use of the complete blood count, differential count, and immature-to-total leukocyte (I:T) ratio for the diagnosis of neonatal sepsis. Shah and Padbury, however, described WBC, absolute neutrophil count, and I:T ratio as having significant limitations in the diagnosis of neonatal sepsis.
1 CRP has been shown to be the best diagnostic marker of neonatal sepsis, with high sensitivity and specificity, 18 but it has low sensitivity during the early phases of infection, due to the time needed for release. 19 Interpretation of CRP in the diagnosis of EOS may be hindered by several non-infectious conditions that influence CRP during the first days after birth. 20 In the present study, P-SEP had better stability than WBC and CRP for 3 days after birth in the non-sepsis term group. 15 Procalcitonin appears to be more specific than CRP in bacterial infection. 21, 22 In neonatal sepsis, PCT concentration increases after 4 h due to the pro-inflammatory actions of bacterial endotoxins, reaching a peak after 6-8 h; thus, a rise in PCT occurs earlier than a rise in CRP. 23 PCT has a dynamic cut-off range 48-72 h after birth, depending on the clinical conditions and setting. PCT results should be interpreted with caution because significant values exceed 1 lg/L during the first 3 days after birth, whereas after the third day of life, a cut-off of 0.5 lg/L offers good sensitivity and specificity. 24 To limit the blood sampling frequency, we did not measure PCT.
If the present results are confirmed in additional studies, we are confident that P-SEP will increase the accuracy of neonatal sepsis screening. The use of P-SEP may also help to decrease false-positive diagnoses and consequent antibiotic overtreatment, which increases the risk of multidrug-resistant bacterial infection or secondary dysmicrobism.
A limitation of the present study was the small number of subjects, especially in the sepsis group. EOS is not often seen in developed countries. The EOS incidence is estimated to be 0.8-1.0 cases/1,000 live births. Therefore, we included patients in the sepsis group from all neonatal ages. Furthermore, sepsis was diagnosed only on the basis of blood culture. We cannot account for the possibility of false-positive or false-negative cultures.
In conclusion, we are confident that P-SEP can better discriminate between infection and non-infectious inflammatory conditions than the currently used biomarkers. CRP, C-reactive protein; P-SEP, presepsin; WBC, white blood cells.
